Literature DB >> 23329382

Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.

Steven Simoens, Eline Picavet, Marc Dooms, David Cassiman, Thomas Morel.   

Abstract

Mesh：

Year:  2013        PMID： 23329382     DOI： 10.1007/s40258-012-0004-y

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN： 1175-5652            Impact factor:   2.561


× No keyword cloud information.
  24 in total

Review 1.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 2.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

3.  Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.

Authors:  Laura Gutierrez; Julien Patris; Adam Hutchings; Warren Cowell
Journal:  Orphanet J Rare Dis       Date:  2015-05-03       Impact factor: 4.123

4.  Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.

Authors:  Michael Ermisch; Anna Bucsics; Patricia Vella Bonanno; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Jurij Fürst; Kristina Garuolienė; Martin van der Graaff; Jolanta Gulbinovič; Alan Haycox; Jan Jones; Roberta Joppi; Ott Laius; Irene Langner; Antony P Martin; Vanda Markovic-Pekovic; Laura McCullagh; Einar Magnusson; Ellen Nilsen; Gisbert Selke; Catherine Sermet; Steven Simoens; Robert Sauermann; Ad Schuurman; Ricardo Ramos; Vera Vlahovic-Palcevski; Corinne Zara; Brian Godman
Journal:  Front Pharmacol       Date:  2016-09-28       Impact factor: 5.810

5.  Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.

Authors:  Katarzyna Kolasa; Krzysztof M Zwolinski; Zoltan Kalo; Tomasz Hermanowski
Journal:  Orphanet J Rare Dis       Date:  2016-03-10       Impact factor: 4.123

6.  The availability and affordability of orphan drugs for rare diseases in China.

Authors:  Shiwei Gong; Yingxiao Wang; Xiaoyun Pan; Liang Zhang; Rui Huang; Xin Chen; Juanjuan Hu; Yi Xu; Si Jin
Journal:  Orphanet J Rare Dis       Date:  2016-02-27       Impact factor: 4.123

7.  Clinical evidence for orphan medicinal products-a cause for concern?

Authors:  Eline Picavet; David Cassiman; Carla E Hollak; Johan A Maertens; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-10-16       Impact factor: 4.123

8.  Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.

Authors:  Thomas Morel; Francis Arickx; Gustaf Befrits; Paolo Siviero; Caroline van der Meijden; Entela Xoxi; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-12-24       Impact factor: 4.123

Review 9.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123

10.  Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.

Authors:  Winnie de Bruijn; Cristina Ibáñez; Pia Frisk; Hanne Bak Pedersen; Ali Alkan; Patricia Vella Bonanno; Ljiljana S Brkičić; Anna Bucsics; Guillaume Dedet; Jaran Eriksen; Joseph O Fadare; Jurij Fürst; Gisselle Gallego; Isabella P Godói; Augusto A Guerra Júnior; Hakkı Gürsöz; Saira Jan; Jan Jones; Roberta Joppi; Saim Kerman; Ott Laius; Newman Madzikwa; Einar Magnússon; Mojca Maticic; Vanda Markovic-Pekovic; Amos Massele; Olayinka Ogunleye; Aisling O'Leary; Jutta Piessnegger; Catherine Sermet; Steven Simoens; Celda Tiroyakgosi; Ilse Truter; Magnus Thyberg; Kristina Tomekova; Magdalena Wladysiuk; Sotiris Vandoros; Elif H Vural; Corinne Zara; Brian Godman
Journal:  Front Pharmacol       Date:  2016-07-22       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.